Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA.
Clin Cancer Res. 2011 Jun 1;17(11):3551-7. doi: 10.1158/1078-0432.CCR-10-3087. Epub 2011 Apr 29.
Defining an adequate resection margin of colorectal cancer liver metastases is essential for optimizing surgical technique. We have attempted to evaluate the resection margin through a combination of histopathologic and genetic analyses.
We evaluated 88 samples of tumor margins from 12 patients with metastatic colon cancer who each underwent partial hepatectomy of one to six liver metastases. Punch biopsies of surrounding liver tissue were obtained at 4, 8, 12, and 16 mm from the tumor border. DNA from these biopsies was analyzed by a sensitive PCR-based technique, called BEAMing, for mutations of KRAS, PIK3CA, APC, or TP53 identified in the corresponding tumor.
Mutations were identified in each patient's resected tumor and used to analyze the 88 samples circumscribing the tumor-normal border. Tumor-specific mutant DNA was detectable in surrounding liver tissue in 5 of these 88 samples, all within 4 mm of the tumor border. Biopsies that were 8, 12, and 16 mm from the macroscopic visible margin were devoid of detectable mutant tumor DNA and of microscopically visible cancer cells. Tumors with a significant radiologic response to chemotherapy were not associated with any increase in mutant tumor DNA in beyond 4 mm of the main tumor.
Mutant tumor-specific DNA can be detected beyond the visible tumor margin, but never beyond 4 mm, even in patients whose tumors were larger prior to chemotherapy. These data provide a rational basis for determining the extent of surgical excision required in patients undergoing resection of liver metastases.
明确结直肠癌肝转移灶的充分切除边界对于优化手术技术至关重要。我们尝试通过组织病理学和遗传学分析相结合的方法来评估切除边界。
我们评估了 12 例转移性结肠癌患者的 88 个肿瘤边缘样本,每位患者均接受了 1 至 6 个肝转移灶的部分肝切除术。在距离肿瘤边界 4、8、12 和 16mm 处从周围肝组织获取穿刺活检。通过一种称为 BEAMing 的基于 PCR 的敏感技术分析这些活检的 DNA,以检测相应肿瘤中 KRAS、PIK3CA、APC 或 TP53 的突变。
在每个患者的切除肿瘤中均发现了突变,并用于分析围绕肿瘤-正常边界的 88 个样本。在这 88 个样本中,有 5 个样本的周围肝组织中可检测到肿瘤特异性突变 DNA,均位于肿瘤边界 4mm 以内。距离肉眼可见的边缘 8、12 和 16mm 的活检未检测到可检测的突变肿瘤 DNA 和显微镜下可见的癌细胞。对化疗有明显影像学反应的肿瘤与主要肿瘤 4mm 以外的突变肿瘤 DNA 增加无关。
即使在化疗前肿瘤较大的患者中,也可在可见肿瘤边缘以外但从未超过 4mm 的范围内检测到肿瘤特异性突变 DNA。这些数据为确定接受肝转移灶切除术的患者所需的手术切除范围提供了合理的依据。